• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Radiol . Integrated assessment of total airway count and pneumonia volume on chest computed tomography as a prognostic biomarker for coronavirus

tetano

Editor, Senior Moderator
Eur Radiol


. 2025 Dec 24.
doi: 10.1007/s00330-025-12078-y. Online ahead of print. Integrated assessment of total airway count and pneumonia volume on chest computed tomography as a prognostic biomarker for coronavirus disease

Kensuke Nakagawara[SUP] #[/SUP][SUP] 1 2 [/SUP], Naoya Tanabe[SUP] #[/SUP][SUP] 3 [/SUP], Shotaro Chubachi[SUP] 4 [/SUP], Tomoki Maetani[SUP] 3 [/SUP], Yusuke Shiraishi[SUP] 3 [/SUP], Takanori Asakura[SUP] 1 5 6 [/SUP], Ho Namkoong[SUP] 7 [/SUP], Hiromu Tanaka[SUP] 1 [/SUP], Takashi Shimada[SUP] 1 [/SUP], Shuhei Azekawa[SUP] 1 [/SUP], Shiro Otake[SUP] 1 [/SUP], Takahiro Fukushima[SUP] 1 [/SUP], Mayuko Watase[SUP] 1 [/SUP], Hideki Terai[SUP] 1 [/SUP], Mamoru Sasaki[SUP] 8 [/SUP], Soichiro Ueda[SUP] 8 [/SUP], Yukari Kato[SUP] 9 [/SUP], Norihiro Harada[SUP] 9 [/SUP], Shoji Suzuki[SUP] 10 [/SUP], Shuichi Yoshida[SUP] 10 [/SUP], Hiroki Tateno[SUP] 10 [/SUP], Yoshitake Yamada[SUP] 11 [/SUP], Masahiro Jinzaki[SUP] 11 [/SUP], Toyohiro Hirai[SUP] 3 [/SUP], Yukinori Okada[SUP] 12 13 14 [/SUP], Ryuji Koike[SUP] 15 [/SUP], Makoto Ishii[SUP] 1 16 [/SUP], Akinori Kimura[SUP] 17 [/SUP], Seiya Imoto[SUP] 18 [/SUP], Satoru Miyano[SUP] 19 [/SUP], Seishi Ogawa[SUP] 20 21 [/SUP], Takanori Kanai[SUP] 22 [/SUP], Koichi Fukunaga[SUP] 1 [/SUP]



Affiliations
Abstract

Objectives: The clinical relevance of computed tomography (CT)-based airway tree structure is unclear. Herein, we used artificial intelligence to segment the airway tree and pneumonia regions, measuring total airway count (TAC) and pneumonia volume to examine whether their combination is more closely associated with clinical outcomes in patients with coronavirus disease (COVID-19) than pneumonia volume alone.
Materials and methods: We examined clinical data and chest CT from 781 hospitalized COVID-19 patients in a multicenter retrospective cohort in Japan, focusing on the percentage of critical outcomes (high-flow oxygen, invasive mechanical ventilation, or death). Additionally, 197 patients were followed up for 3 months to monitor TAC and pneumonia volume.
Results: Critical outcomes were observed in 63 (8.8%) patients, with higher TAC in those patients. Patients were divided into four groups based on cutoff values of 17.6% for pneumonia volume percent and 255 for TAC: Group A (low TAC, low pneumonia volume), Group B (high TAC, low pneumonia volume), Group C (low TAC, high pneumonia volume), and Group D (high TAC, high pneumonia volume). Group D had the worst outcomes, highest levels of inflammation, fibrosis markers, and complications, as well as a significantly higher risk of critical outcomes after adjusting for age, body mass index, sex, total lung volume and comorbidities. In the 3-month longitudinal analysis, pneumonia volume, but not TAC, improved in critical cases.
Conclusions: The integrated assessment of TAC and pneumonia volume effectively predicted critical outcomes in COVID-19 patients and may be useful for various respiratory diseases, including infectious or interstitial pneumonia.
Key points: Question Total airway counts (TAC) on computed tomography (CT) scan is associated with respiratory disease progression, but clinical relevance of CT-based airway tree structure is unclear. Findings The integrated assessment of TAC and pneumonia volume effectively predicted critical outcomes in COVID-19 patients. Clinical relevance This metric can potentially be applied to various respiratory diseases, including infectious or interstitial pneumonia.

Keywords: Artificial intelligence (AI)-based analysis; COVID-19; CT; SARS-CoV-2 infection; Total airway count.

 
Back
Top